A Virginia middle school student won $25,000 in 3M’s 2023 Young Scientist Challenge for inventing a bar of soap that could help fight skin cancer. (Washington Post)
Oncologists who received payments from pharmaceutical companies were more likely to give their patients low-value cancer drugs compared with their peers who didn’t receive payments. (The BMJ)
Senate Health Committee Chair Bernie Sanders (I-VT) is asking the inspector general of the Department of Health and Human Services to investigate the NIH’s proposal to grant a patent to a small “obscure” company for a CAR-T cell therapy for cervical cancer. (Endpoint News)
A $1,000 multi-cancer early-detection test may find signs of cancer in your blood — but researchers and doctors disagree about its benefits and risks. (Wall Street Journal)
The FDA approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes with an isocitrate dehydrogenase-1 mutation.
An Iowa woman who raised nearly $40,000 by faking multiple cancers will pay restitution but avoid jail time. (USA Today)
Exposure to PFAS “forever chemicals” was linked with higher risk of developing thyroid cancer. (eBioMedicine)
In a study evaluating the effect of cerebrospinal fluid (CSF) on glioblastoma tumors, Australian researchers found that chemoradiation loses efficacy in CSF, but that combining trifluoperazine with standard-of-care treatment may improve survival in those patients. (Science Advances)
Results from the HEM-POWR study demonstrated that over a 33-month period treatment with damoctocog alfa pegol resulted in reduced annualized bleeding rates in previously treated patients with severe and non-severe hemophilia A. (European Journal of Haematology)
The EPA proposed banning all uses of trichloroethylene — an industrial solvent that is used in glues, spot removers, and metal cleaners and has been linked to cancer, as well as damage to the nervous system. (New York Times).
The FDA granted accelerated approval to entrectinib (Rozlytrek) for pediatric patients older than 1 month with solid tumors that have a neurotrophic tyrosine receptor kinase gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy.
Source link : https://www.medpagetoday.com/hematologyoncology/othercancers/107042
Publish date : 2023-10-27 10:47:39
Copyright for syndicated content belongs to the linked Source.